OR WAIT null SECS
The collaboration, which has been in place since 1998, will focus on drug discovery, translational medicine research, and pharmaceutical development.
Syngene announced on April 26, 2021 that it has extended its research collaboration with Bristol Myers Squibb through the end of 2030.
The collaboration, which has been in place since 1998, will focus on drug discovery including chemistry, biology, drug metabolism, and pharmacokinetics, along with translational medicine research and pharmaceutical development, including chemical process development and analytical sciences, Sygene said in a company press release. The partnership extension will also include a 40% increase in the number of scientists and the addition of a new 50,000-ft2 dedicated laboratory space.
"For more than 20 years we have considered our work with Bristol Myers Squibb to set the benchmark for integrated research collaborations and are delighted with our joint commitment to extend this collaboration until at least the end of the decade, as well as expand our focus to new areas of science,” said Jonathan Hunt, MD, CEO, Syngene, in the press release. “I have every confidence that together we will continue to deliver science that will improve the lives of patients around the world."
"We greatly value our collaboration with Syngene International and are proud to extend and expand our work together,” added Gregory Vite, PhD, senior vice-president, Small Molecule Drug Discovery, Bristol Myers Squibb, in the press release. “The dedicated facilities and scientific team at Syngene play an important role in helping us realize our vision to transform patients’ lives through science.”